Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Apr 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Apr 2028
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2010 to 2036.
US 8,536,130
Use of 1-Phenyl-3-Dimethylamino-PROPANE Compounds for Treating Neuropathic Pain
Sep 22, 2028
201520202025203020352036
2 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2028 · High confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Apr 2028 · Medium confidence
Abuse-Deterrent Drug Formulations
US 7,771,707
The most cited patent in this portfolio, cited by 112 later US patents, top 10% of utility patents granted in 2010 in our data. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Process of Making Stable Abuse-Deterrent Oral Formulations
US 9,968,598
Cited by 11 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Titration of Tapentadol
US 11,344,512
Granted 2022. Computed term ends 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 12, 2027The maintenance fee for Process of Making Stable Abuse-Deterrent Oral Formulations (US 10,646,485) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Process of Making Stable Abuse-Deterrent Oral Formulations | 4 in force | to Sep 2036 |
| Abuse-Deterrent Drug Formulations | 1 in force | to Oct 2028 |
| Use of 1-Phenyl-3-Dimethylamino-PROPANE Compounds for Treating Neuropathic Pain | 1 in force | to Sep 2028 |
| Titration of Tapentadol | 1 in force | to Apr 2028 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,344,512 | Titration of Tapentadol In force · Medium confidence | In force | Medium confidence | |
| US 8,536,130 | Use of 1-Phenyl-3-Dimethylamino-PROPANE Compounds for Treating Neuropathic Pain In force · Medium confidence | In force | Medium confidence | |
| US 7,771,707 | Abuse-Deterrent Drug Formulations In force · High confidence | In force | High confidence | |
| US 9,737,530 | Process of Making Stable Abuse-Deterrent Oral Formulations In force · High confidence | In force | High confidence | |
| US 9,968,598 | Process of Making Stable Abuse-Deterrent Oral Formulations In force · High confidence | In force | High confidence | |
| US 10,188,644 | Process of Making Stable Abuse-Deterrent Oral Formulations In force · High confidence | In force | High confidence | |
| US 10,646,485 | Process of Making Stable Abuse-Deterrent Oral Formulations In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 25 patents ended · 2 applications pending · 50 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.